Silver Book Fact

New Medicines in Development for Parkinson’s Disease in 2018

Fact image

America's Biopharmaceutical Companies. Medicines in Development for Neurological Disorders: 2018 Report. Washington, D.C.: PhRMA; 2018. https://www.phrma.org/report/medicines-in-development-for-neurological-disorders-2018-report. Accessed June 11, 2019

Reference

Title
Medicines in Development for Neurological Disorders: 2018 Report
Publication
PhRMA
Publisher
PhRMA
Publication Date
2018
Authors
America's Biopharmaceutical Companies
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years were introduced in 2015, by 2050 the total reduction in cost of care for people…  
  • Around 75 – 100 experimental therapies that are aimed at slowing or stopping the progression of Alzheimer’s disease are currently in clinical trials.  
  • Delaying the onset and progression of Alzheimer’s disease would reduce the projected number of people with moderate to severe cases of the disase to 4.4 million instead of 10.3 million…  
  • Deep brain stimulation, an electrical signal delivered deep inside the brain, provides significant symptomatic relief for Parkinson’s patients whose medication is no longer effective.  
  • Research breakthroughs that slow the onset and progression of Alzheimer’s disease could achieve annual Medicare savings of $51 billion by 2015, $126 billion by 2025, and $444 billion by 2050.